Nothing Special   »   [go: up one dir, main page]

DK2925338T3 - Frysetørret formulering af tat-nr2b9c - Google Patents

Frysetørret formulering af tat-nr2b9c Download PDF

Info

Publication number
DK2925338T3
DK2925338T3 DK13859059.1T DK13859059T DK2925338T3 DK 2925338 T3 DK2925338 T3 DK 2925338T3 DK 13859059 T DK13859059 T DK 13859059T DK 2925338 T3 DK2925338 T3 DK 2925338T3
Authority
DK
Denmark
Prior art keywords
nr2b9c
tat
freeze
dried formulation
formulation
Prior art date
Application number
DK13859059.1T
Other languages
English (en)
Inventor
Jonathan David Garman
Original Assignee
Nono Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc filed Critical Nono Inc
Application granted granted Critical
Publication of DK2925338T3 publication Critical patent/DK2925338T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK13859059.1T 2012-11-28 2013-11-25 Frysetørret formulering af tat-nr2b9c DK2925338T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730952P 2012-11-28 2012-11-28
PCT/US2013/071755 WO2014085349A1 (en) 2012-11-28 2013-11-25 Lyophilized formulation of tat-nr2b9c

Publications (1)

Publication Number Publication Date
DK2925338T3 true DK2925338T3 (da) 2019-05-06

Family

ID=50828392

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13859059.1T DK2925338T3 (da) 2012-11-28 2013-11-25 Frysetørret formulering af tat-nr2b9c

Country Status (19)

Country Link
US (1) US20140162957A1 (da)
EP (1) EP2925338B8 (da)
JP (1) JP6427104B2 (da)
KR (1) KR102166374B1 (da)
CN (2) CN105101986B (da)
AU (1) AU2013352437B2 (da)
CA (1) CA2892965C (da)
DK (1) DK2925338T3 (da)
ES (1) ES2725598T3 (da)
HK (1) HK1215793A1 (da)
HR (1) HRP20190707T1 (da)
HU (1) HUE043820T2 (da)
LT (1) LT2925338T (da)
MX (1) MX365325B (da)
PL (1) PL2925338T3 (da)
PT (1) PT2925338T (da)
SI (1) SI2925338T1 (da)
TR (1) TR201905787T4 (da)
WO (1) WO2014085349A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
JP6707469B2 (ja) * 2014-05-28 2020-06-10 ノノ インコーポレイテッド アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤
LT3149048T (lt) 2014-05-28 2020-05-11 Nono Inc. Tat-nr2b9c chlorido druska
WO2016115561A1 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
JP2019522675A (ja) * 2016-04-27 2019-08-15 ▲拝▼西欧斯(北京)生物技▲術▼有限公司 興奮製神経毒性に関連した損傷の治療方法
CN106619170A (zh) * 2016-10-26 2017-05-10 暨南大学 包含stp和生长因子的活性组合物及其化妆品或护肤品
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US7858322B2 (en) * 2003-12-23 2010-12-28 Nono, Inc. Method of determining inhibition of binding to TRPM7 protein
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
EP1910552A4 (en) * 2005-06-23 2009-01-07 Arbor Vita Corp METHOD AND COMPOSITIONS FOR MODULATING COX
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
EP2021474A2 (en) * 2006-05-05 2009-02-11 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
US8933013B2 (en) * 2007-12-05 2015-01-13 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
CA2739416C (en) * 2008-09-03 2017-10-31 Arbor Vita Corporation Agents and methods for treatment of pain
US8099602B2 (en) * 2008-09-26 2012-01-17 Mykonos Software, Inc. Methods for integrating security in network communications and systems thereof
DK2440230T3 (da) * 2009-06-10 2021-01-18 Nono Inc Behandlingsregimener til behandling af neurologisk sygdom
WO2012021854A2 (en) * 2010-08-12 2012-02-16 Nono, Inc. Treatment of penetrative injury to the brain

Also Published As

Publication number Publication date
EP2925338B8 (en) 2019-05-22
BR112015012422A2 (pt) 2017-09-12
EP2925338A4 (en) 2016-05-25
AU2013352437A1 (en) 2015-07-09
HRP20190707T1 (hr) 2019-10-04
CN105101986A (zh) 2015-11-25
WO2014085349A1 (en) 2014-06-05
KR102166374B1 (ko) 2020-10-15
AU2013352437B2 (en) 2018-04-12
CN109106941A (zh) 2019-01-01
KR20150094656A (ko) 2015-08-19
HK1215793A1 (zh) 2016-09-15
US20140162957A1 (en) 2014-06-12
HUE043820T2 (hu) 2019-09-30
EP2925338A1 (en) 2015-10-07
PL2925338T3 (pl) 2019-11-29
CN105101986B (zh) 2018-09-25
CA2892965C (en) 2021-06-01
LT2925338T (lt) 2019-05-10
JP2016502537A (ja) 2016-01-28
MX365325B (es) 2019-05-29
ES2725598T3 (es) 2019-09-25
SI2925338T1 (sl) 2019-09-30
MX2015006784A (es) 2015-10-29
EP2925338B1 (en) 2019-03-27
JP6427104B2 (ja) 2018-11-21
TR201905787T4 (tr) 2019-05-21
CA2892965A1 (en) 2014-06-05
PT2925338T (pt) 2019-05-31

Similar Documents

Publication Publication Date Title
DK3725778T3 (da) Formuleringer af enzalutamid
CO7061086A2 (es) Combinaciones de compuestos activos
DK3336097T3 (da) Fremstilling af ikke-krystallinsk obeticholsyre
DK2845905T3 (da) Fremstilling af oligosaccharider
DK2858671T3 (da) Antistofformulering
BR112015002651A2 (pt) composições cosméticas
CO6801776A2 (es) Cosmético
DK2890397T3 (da) Antiprolactinreceptor-antistofformulering
BR112014032798A2 (pt) composição
DK2846809T3 (da) Behandling af myelosuppression
AR092198A1 (es) Derivados de pirazolopirimidinas
DK2925338T3 (da) Frysetørret formulering af tat-nr2b9c
DK3461895T3 (da) Modulation af ube3a-ats-ekspression
DK2841054T3 (da) Injicerbart præparat
DK2822568T3 (da) Anvendelser af caseinsammensætninger
BR112014029176A2 (pt) formulações injetáveis de aprepitante
DK2827862T3 (da) Formuleringer af bendamustin
BR112014000015A2 (pt) formulação
DK2868318T3 (da) Injicerbar formulering
DK2897594T3 (da) Farmaceutisk sammensætning
DK2894998T3 (da) Rotation af kegle
DK2854831T3 (da) Fremstilling af degarelix
DK2812013T3 (da) Formulering til behandling af IBS
BR112014032712A2 (pt) composição
FR2995524B1 (fr) Prothese endo-urinaire